Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease

https://www.prnewswire.com/news-releases/bird-rock-bio-announces-successful-completion-of-phase-1b-safety-study-and-readiness-for-phase-2b-study-of-nimacimab-in-patients-with-diabetic-kidney-disease-300940218.html

About Bird Rock Bio, Inc.

Backed by leading biotechnology venture investors, Bird Rock Bio's strategy leverages biologic targets with substantial human proof of mechanism for the development of first in class or best in class molecules with strong clinical and commercial differentiation. The Company is focused on developing proprietary antibodies for fibrotic, metabolic and inflammatory diseases. Bird Rock Bio's science team is experienced with translating pioneering research into promising therapeutics with potential deep pharmacoeconomic benefits. For more, visit www.birdrockbio.com.